Transcept Gets FDA Response Letter - reity

Sign Up | Log In | What is SocialPicks?

Please sign up for SocialPicks site access - it's free!

Transcept Gets FDA Response Letter
Oct 29, 2009 11:09 AM UTC

reity

Return	Risk
-33.88%	HIGH

Analyst

Profile & Performance

Subscribe to author

Symbol	Sentiment	Start	Return	Closed
NDA	n/a
CRL	n/a

Via Zacks Equity Research Analyst Blog:

The U.S. FDA issued a complete response letter (CRL) on Transcept's new drug application (NDA) for Intermezzo.

Read the rest of original post »

Add Comment

Be the first to comment on this story and earn 2 points.

Your Comment

IN THE PRESS

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.